We believe that Biogen stock, a biotechnology company focused on treatments for neurological diseases, is a good buying opportunity at the present time. BIIB stock trades near $250 currently and it is, in fact, down 27% from its pre-Covid high of around $340 in February 2020...
We believe that Biogen stock, a biotechnology company focused on treatments for neurological diseases, is a good buying opportunity at the present time. BIIB stock trades near $250 currently and it is, in fact, down 27% from its pre-Covid high of around $340 in February 2020...
Share this Article
Recommended